Business & Industry

DeepCyte, a techbio company focused on advancing AI Drug Toxicology, has launched with $1.5 million in seed funding. The company is introducing two integrated solutions aimed at helping biopharma teams detect, predict, and explain drug toxicity directly in human...

Halozyme Therapeutics has entered into a global exclusive partnership and licence agreement with Vertex Pharmaceuticals through its subsidiary Halozyme Hypercon, marking a new step in advancing drug delivery capabilities. The deal gives Vertex access to the Hypercon platform, which...

Gilead Sciences has agreed to acquire Germany-based Tubulis in a deal valued at $3.15 billion upfront, with an additional $1.85 billion tied to milestones, as the company advances its position in the rapidly evolving antibody-drug conjugate segment. The acquisition...

Neurocrine Biosciences is close to securing a more than $2.5bn acquisition of Soleno Therapeutics, the developer of a treatment for a rare genetic form of obesity. The talks, described as advanced, highlight how midsized drugmakers are increasingly pursuing strategic...

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, in a move that significantly expands its presence in immunology and rare diseases. The Biogen to Acquire Apellis deal stands among the company’s largest transactions to date,...

The US pharma tariffs policy has been formalised through an executive order signed by Donald Trump, introducing tariffs of up to 100% on imported branded medicines. The measure targets pharmaceutical companies that have not entered into drug pricing agreements...

Britain has finalised a UK-US pharma trade deal, securing tariff-free access for UK-made medicines to the United States while committing to higher domestic spending and pricing adjustments for new drugs. The agreement, part of a broader bilateral trade framework...